Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

US SEC imposes fine on Bio-Rad over FCPA violations

The US Securities and Exchange Commission (SEC) has imposed a fine on clinical diagnostic and life science research company Bio-Rad Laboratories for violating the Foreign Corrupt Practices Act (FCPA).

Bio-Rad agreed to pay $55m to settle the SEC’s charges, which included $40.7m in disgorgement and prejudgment interest to the SEC and a $14.35m criminal fine to the Department of Justice.

In addition, the company has to report its FCPA compliance efforts to the SEC for a period of two years.

SEC enforcement division director Andrew Ceresney said: "Bio-Rad Laboratories failed to detect a bribery scheme and did not properly address red flags that such a scheme was underway.

"This enforcement action, which reflects credit for Bio-Rad’s cooperation in our investigation, reiterates the importance of all companies ensuring they have the proper internal controls to prevent FCPA violations."

Bio-Rad’s subsidiaries were involved in improper payments to foreign officials in Russia, Vietnam, and Thailand, in a bid to secure business.

The investigation of SEC revealed that Bio-Rad lacked sufficient internal controls to prevent or detect around $7.5m in bribes, which were paid during a five-year period.

According to SEC, the improper payments allowed the company to earn around $35m in illicit profits.